Acurx Forms New Partnership to Enhance Development of Antibiotic Treatment Against Drug-Resistant Infections#United_States#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development#DNA_Polymerase_IIIC
Acurx Forms New Partnership to Enhance Development of Antibiotic Treatment Against Drug-Resistant Infections
Acurx Pharmaceuticals collaborates with Leiden University Medical Center to create innovative DNA Polymerase IIIC inhibitor antibiotics, targeting MRSA infections.
third-news.com
August 10, 2026 at 12:13 PM
Acurx Forms New Partnership to Enhance Development of Antibiotic Treatment Against Drug-Resistant Infections#United_States#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development#DNA_Polymerase_IIIC
Acurx Pharmaceuticals Secures New Patent for Innovative DNA Polymerase IIIC Inhibitors#United_States#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development#DNA_Polymerase_IIIC
Acurx Pharmaceuticals Secures New Patent for Innovative DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals has been granted a new patent for DNA Polymerase IIIC inhibitors, enhancing its portfolio in antibiotic development and treatment for severe bacterial infections.
third-news.com
March 30, 2026 at 11:10 AM
Acurx Pharmaceuticals Secures New Patent for Innovative DNA Polymerase IIIC Inhibitors#United_States#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development#DNA_Polymerase_IIIC
Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates#USA#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development
Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates
Acurx Pharmaceuticals delivers an encouraging financial report for Q1 2025, highlighting advancements in antibiotic development and strategic partnerships.
third-news.com
May 13, 2025 at 11:06 AM
Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates#USA#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development
Acurx Pharmaceuticals Secures $2.5 Million in Direct Stock Offering Amid Development of New Antibiotic Class#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development
Acurx Pharmaceuticals Secures $2.5 Million in Direct Stock Offering Amid Development of New Antibiotic Class
Acurx Pharmaceuticals has successfully closed a $2.5 million direct offering of its common stock, designed to fund the development of innovative antibiotics targeting resistant bacterial infections.
third-news.com
January 7, 2025 at 10:06 PM
Acurx Pharmaceuticals Secures $2.5 Million in Direct Stock Offering Amid Development of New Antibiotic Class#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development